Literature DB >> 18538862

Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.

Cristina Ulivieri1, Alessandra Citro, Federico Ivaldi, Dina Mascolo, Raffaella Ghittoni, Daniela Fanigliulo, Fabrizio Manca, Cosima Tatiana Baldari, Giuseppina Li Pira, Giovanna Del Pozzo.   

Abstract

Several efforts have been invested in the identification of CTL and Th epitopes, as well as in the characterization of their immunodominance and MHC restriction, for the generation of a peptide-based HCMV vaccine. Small synthetic peptides are, however, poor antigens and carrier proteins are important for improving the efficacy of synthetic peptide vaccines. Recombinant bacteriophages appear as promising tools in the design of subunit vaccines. To investigate the antigenicity of peptides carried by recombinant bacteriophages we displayed different HCMV MHCII restricted peptides on the capsid of filamentous bacteriophage (fd) and found that hybrid bacteriophages are processed by human APC and activate HCMV-specific CD4 T-cells. Furthermore we constructed a reporter T-cell hybridoma expressing a chimeric TCR comprising murine alphabeta constant regions and human variable regions specific for the HLA-A2 restricted immunodominant NLV peptide of HCMV. Using the filamentous bacteriophage as an epitope carrier, we detected a more robust and long lasting response of the reporter T-cell hybridoma compared to peptide stimulation. Our results show a general enhancement of T-cell responses when antigenic peptides are carried by phages.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538862     DOI: 10.1016/j.imlet.2008.04.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

Review 1.  Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Authors:  Hamidreza Hashemi; Somayeh Pouyanfard; Mojgan Bandehpour; Zahra Noroozbabaei; Bahram Kazemi; Xavier Saelens; Talat Mokhtari-Azad
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

3.  Phage proteins are expressed on the surface of Neisseria gonorrhoeae and are potential vaccine candidates.

Authors:  Aneta Kłyż; Andrzej Piekarowicz
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

4.  Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice.

Authors:  Atefeh Razazan; Jessica Nicastro; Roderick Slavcev; Nastaran Barati; Atefeh Arab; Fatemeh Mosaffa; Mahmoud Reza Jaafari; Javad Behravan
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

Review 5.  Arming Filamentous Bacteriophage, a Nature-Made Nanoparticle, for New Vaccine and Immunotherapeutic Strategies.

Authors:  Rossella Sartorius; Luciana D'Apice; Antonella Prisco; Piergiuseppe De Berardinis
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

Review 6.  Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold.

Authors:  Kevin A Henry; Mehdi Arbabi-Ghahroudi; Jamie K Scott
Journal:  Front Microbiol       Date:  2015-08-04       Impact factor: 5.640

7.  Oral Immunization of Rabbits with S. enterica Typhimurium Expressing Neisseria gonorrhoeae Filamentous Phage Φ6 Induces Bactericidal Antibodies Against N. gonorrhoeae.

Authors:  Andrzej Piekarowicz; Aneta Kłyż; Michał Majchrzak; Daniel C Stein
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

Review 8.  Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.

Authors:  Tatiana I Samoylova; Timothy D Braden; Jennifer A Spencer; Frank F Bartol
Journal:  Curr Med Chem       Date:  2017-11-20       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.